Compare Levi Strauss & Co. (LEVI) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Medtronic PLC — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 15.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Medtronic PLC for 63 Days on average.
| LEVI | MDT | |
|---|---|---|
Market Cap | $7.31B | $112.24B |
Volume | 13,683,095 | 105,663,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $105.35 |
52-Week Low | $17.92 | $73.75 |
Typical Hold Time | 70 Days | 63 Days |
Enterprise Value | $8.86B | $131.58B |
Dividend Yield | 3.36% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.53 and P/S of 1.12, while profitability remains solid with a net income margin of 8.83% and ROE of 25.76%.
Wall Street maintains a bullish stance with 15 buy ratings and a consensus price target of $29.00, implying significant upside. However, technical indicators show bearish momentum, and risks include competitive pressures and recent cybersecurity incidents. The stock's current price near recent support levels presents a potential entry point for value-oriented investors.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
